Volex (VLX) Completes $89.4 Million Acquisition of Remaining 64.3% Stake in Kepler SignalTek, Securing Full Ownership

Volex Finalizes Full Ownership of Kepler SignalTek in $89.4 Million Deal on 14 July 2026

Volex plc confirmed on 14 July 2026 that it has acquired the remaining 64.3% of Kepler SignalTek Ltd, a company in which it held a 35.7% minority stake since KST’s inception in 2017. This acquisition marks approximately nine years of partnership and investment in KST by Volex. The signing and completion occurred simultaneously on 14 July 2026, with no outstanding regulatory conditions, making the transaction effective immediately.

The total consideration of up to $89.4 million is structured on a cash-free, debt-free basis, comprising an initial cash payment of about $74.7 million at completion, subject to customary net debt and working capital adjustments, and deferred payments of up to $14.7 million payable in two installments over the following two anniversaries. These deferred payments are contingent on KST achieving designated revenue milestones and include certain amounts allocated to KST employees. The acquisition is financed through Volex’s existing debt facilities.

Kepler SignalTek’s Patient-Connected Medical Products and Manufacturing Locations

KST specializes in manufacturing patient-connected medical products, including single-use and reusable cables and devices employed in patient monitoring, surgical procedures, cardiac therapy, and ultrasound imaging. Unlike Volex’s existing Medical segment, which focuses on complex cable assemblies within medical equipment such as MRI scanners and robotic surgery devices, KST’s products are designed for direct clinical patient interaction.

KST operates manufacturing facilities in Dongguan, China, and Batam, Indonesia. Founded in 2017 by Scott Hayden, who will continue to lead the company alongside the experienced management team post-acquisition, this operational continuity is a key factor. Previously equity-accounted as an associate, KST will now be consolidated as a subsidiary within Volex’s Medical segment.

KST Reports $51.8 Million Revenue in FY2026 with 10% Organic Growth

For the fiscal year ending 31 March 2026, KST generated $51.8 million in revenue, up from $47.0 million the previous year, representing a 10% organic increase. This growth underscores the company’s strong commercial momentum ahead of the acquisition. The deferred consideration structure tied to performance highlights the strategic value of this acquisition for Volex.

The acquisition is expected to be immediately accretive to Volex’s earnings from completion. KST’s EBIT margin surpasses Volex’s underlying operating margin, indicating a margin-enhancing addition. Volex anticipates achieving a return on capital employed exceeding 15% within two years, aligning with targets set during its April 2026 Capital Markets Day. Investors and analysts will closely evaluate these financial impacts.

Expansion of Volex’s Medical Business into Clinical Patient-Connected Solutions

Volex’s Medical division has traditionally focused on complex cable assemblies within medical devices. The full acquisition of KST strategically extends Volex’s portfolio into patient-connected products used directly in clinical care. This complementary product category offers limited customer overlap, presenting significant cross-selling opportunities.

The limited overlap between KST and Volex’s existing Medical customers is viewed as a commercial advantage. Volex aims to leverage its global healthcare technology relationships to accelerate KST’s growth, while KST’s established clinical product connections will broaden Volex’s market access. This reciprocal cross-selling potential is expected to drive expansion for both entities.

Longstanding Partnership with KST Founder Scott Hayden Reinforces Acquisition Confidence

Volex’s nearly decade-long investment in KST since its founding by Scott Hayden in 2017 has allowed thorough evaluation of the company’s management, customer base, technology, and financials. This enduring relationship underpins Volex’s confidence in acquiring the remaining stake at this stage.

CEO Nat Rothschild commented: "Volex has been an investor in Kepler SignalTek since Scott Hayden founded the business in 2017, supporting its growth throughout. We know the business, team, and customers well, and believe integrating with Volex’s global platform is the natural progression." He added, "This acquisition extends Volex from manufacturing internal medical equipment cables to supplying products that connect equipment directly to patients, with minimal customer overlap and clear growth prospects." These forward-looking statements are subject to risks and uncertainties as noted in the announcement.

Post-Acquisition Balance Sheet and Pro-Forma Leverage at Approximately 1.1x

The acquisition is funded through Volex’s existing debt facilities. Post-transaction, the Group expects to maintain a strong balance sheet with pro-forma covenant leverage of about 1.1x, up from 0.8x as of 31 March 2026. The increase reflects the $74.7 million initial cash payment funded by debt, with deferred payments of up to $14.7 million adding to future cash outflows contingent on KST’s revenue performance.

Volex indicates this leverage position preserves financial flexibility to pursue further acquisitions, suggesting the KST deal does not exhaust its acquisition capacity. The moderate leverage increase and expected returns above 15% on capital employed imply potential deleveraging through earnings growth. Investors will monitor how quickly KST’s earnings contribute to reducing leverage ahead of additional transactions.

Alignment with Volex’s $2 Billion Revenue and 12% Margin Medium-Term Strategy

This acquisition aligns with Volex’s medium-term strategic plan announced at its April 2026 Capital Markets Day, targeting $2 billion in revenue and a 12% underlying operating margin. The KST deal meets the 15% return on capital employed criterion and supports expanding a higher-margin Medical business.

Volex operates across five end-markets: Complex Industrial Technology, Consumer Electricals, EV and Electrification, Medical, and Off-Highway. Headquartered in the UK, it runs 23 manufacturing sites and employs approximately 12,500 people in 25 countries. Its products serve Original Equipment Manufacturers and Electronic Manufacturing Services globally. KST’s $51.8 million revenue base contributes meaningfully toward the $2 billion target, especially with anticipated cross-selling synergies and accelerated growth via Volex’s global platform.

Geographic Manufacturing Risks in Dongguan and Batam Facilities

KST’s manufacturing footprint includes two sites: Dongguan, China, and Batam, Indonesia. This concentration presents geographic risk factors, including geopolitical, tariff, and regulatory challenges, especially pertinent in the medical device sector where quality and compliance are critical. While the Batam facility offers some diversification, the Asian manufacturing concentration should be considered by investors assessing risk-adjusted returns.

Volex’s broader network of 23 manufacturing sites across 25 countries provides wider geographic diversification. However, the announcement does not specify whether KST’s operations will be integrated into Volex’s global manufacturing footprint or detail regulatory approvals for KST’s patient-connected products. Additionally, specific revenue thresholds triggering the deferred consideration payments remain undisclosed, factors important for evaluating acquisition risks.

Accounting Transition: KST Moves from Associate to Subsidiary in Volex’s Financials

Following completion on 14 July 2026, KST will transition from being equity-accounted as an associate to full consolidation as a subsidiary within Volex’s Medical segment. This change means KST’s revenues, expenses, assets, and liabilities will be included line-by-line in Volex’s consolidated financial statements rather than reflected as a share of associate profits.

This accounting shift will significantly impact reported revenue and operating profit, incorporating KST’s $51.8 million FY2026 revenue and its EBIT margin, which exceeds the Group’s underlying margin. Although the acquisition is expected to enhance underlying earnings immediately, acquisition-related accounting charges such as fair value adjustments and intangible asset amortization may affect reported earnings in the short term. The announcement does not disclose the magnitude of these charges.